Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label,…
By L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. R. De La Haba-Rodríguez, S. Im and 10 more. The Lancet Oncology, 2012
2,018 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/9fcca546719b326999f61f50111e4548240d1b4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “The randomized phase II and III trials included in the review are summarized in the Data Supplement Table 1 (online only).(9-25,26-55) The included RCTs addressed the use of neoadjuvant systemic therapy in patients with high-risk HER2-positive or TNBC; specific neoadjuvant systemic therapy regimens ”